R&D | March 10, 2026
UK pushes space-made medicines from orbit to patients with new support package
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
